Update on the release and availability of OLINDA version 2.0
HERMES Medical Solutions and Vanderbilt University announce exclusive license and commercialization agreement
Stockholm, Sweden and Nashville, Tennessee, U.S. 9/10/2015
HERMES Medical Solutions (HERMES) by Sofia Bertling COO and Vanderbilt University (Vanderbilt) by Professor Michael Stabin announced today the signature of an exclusive license and commercialization agreement for the new dosimetry application OLINDA / EXM® to be distributed by HERMES. The OLINDA / EXM® application is widely used in the radiopharmaceutical industry and research community for internal dose calculations of radiopharmaceuticals. The new version has been enhanced and includes new human models and nuclides. HERMES will continue the development, regulatory, manufacturing and commercial leadership of OLINDA / EXM®. https://www.hermesmedical.com/dosimetry/
Description
The OLINDA/EXM® personal computer code performs dose calculations and kinetic modeling for radiopharmaceuticals (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). OLINDA® calculates radiation doses to different organs of the body from systemically administered radiopharmaceuticals and performs regression analysis on user-supplied biokinetic data to support such calculations for nuclear medicine drugs.
These calculations are used to perform risk/ benefit evaluations of the use of such pharmaceuticals in diagnostic and therapeutic applications in nuclear medicine. The technology employs a number of stan- dard body models for adults, children, pregnant women and others, that are widely accepted and used in the internal dose community. The calculations are useful to pharmaceutical industry developers, nuclear medicine professionals, educators, regulators, researchers and others who study the accepted radiation doses that should be delivered when radioactive drugs are given to patients or research subjects.